Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea.
| Website | http://www.foamix.com |
| Employees | 32 (14 on RocketReach) |
| Founded | 2003 |
| Technologies | |
| Industry | Topical, Pharmaceutical Manufacturing, Pharmaceuticals, Formulation, Drug Delivery, Dermatology, Gynecology, Foam, Skin, Psoriasis, Atopic Dermatitis, Acne, Rosacea, Wound, Burn |
| Competitors | Ipsen, Galderma, Bausch Health Companies Inc., Valeant Pharmaceuticals, Revance, Evolus, Aclaris Therapeutics, Inc., Sientra, Inc., MediNatura Inc., Hugel Inc. +38 more (view full list) |
Looking for a particular Foamix employee's phone or email?
David Schuz is the Senior Vice President of Foamix.
14 people are employed at Foamix.
Foamix is based in Rehovot, Central District.